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Abstract
Objectives Perfluorooctanoic acid (PFOA) results in
peroxisome proliferator mediated effects in rats and mice
resulting in hypolipidemia but not in monkeys. Counter-
intuitive modestly positive associations between PFOA and
cholesterol levels in production workers have been incon-
sistently reported. The purpose of this assessment was to
examine this association in male workers who manufac-
tured or used PFOA at three facilities.
Methods Subjects were male employee voluntary partic-
ipants of a fluorochemical medical surveillance program
who provided blood samples for serum measurement of
PFOA (perfluorooctanoate) and various lipid, hepatic, and
thyroid parameters. Statistical analyses included multiple
and logistic regression and analysis of covariance.
Results A total of 506 employees, who did not take
cholesterol-lowering medications (93% of all male par-
ticipants), were analyzed. Serum PFOA concentrations
ranged from 0.007 to 92.03 lg/ml [arithmetic mean
2.21 lg/ml (95% confidence interval 1.66–2.77), median
1.10 lg/ml]. Adjusted for age, body mass index, and
alcohol usage in regression analyses, PFOA was not sta-
tistically significantly (P > 0.05) associated with total
cholesterol or low-density lipoproteins (LDL). High-den-
sity lipoproteins (HDL) were significantly negatively
(P < 0.01) associated with PFOA for the three facilities
combined but not by individual sites, indicating the overall
result was likely a consequence of residual confounding
due to different demographic profiles at these sites. Serum
triglycerides were significantly positively associated with
PFOA but not consistently by locations. There were no
statistically significant associations observed between
PFOA and hepatic enzymes for the three facilities com-
bined although some modest positive associations were
observed between PFOA and hepatic enzymes at one of
the three facilities. Analyses of all locations showed no
associations with TSH or T4 and PFOA. A negative
association was observed for free T4 and positive associ-
ation for T3; however, the findings were well within these
assays’ normal reference ranges.
Conclusion There was no evidence that employees’ ser-
um PFOA concentrations were associated with total cho-
lesterol or LDL. A negative association with HDL was
explained by demographic differences across the three
locations. Several explanations are offered for the incon-
sistent triglyceride associations with PFOA including both
methodological as well as biological possibilities.
Keywords Perfluorooctanoate  PFOA  Fluorochemicals 
Cholesterol  Lipids
Introduction
The ammonium salt of perfluorooctanoic acid (APFO),
which rapidly dissociates in blood to perfluorooctanoate
(PFOA, C7F15COO
–), has been used as a processing aid in
the production of various fluoropolymers. The widespread
presence of PFOA in the blood of the general population
(Calafat et al. 2006) has resulted in assessments of sources
of exposure including industrial production, indirect sour-
ces including atmospheric production, and transport of
telomer precursors (De Silva and Maybury 2006).
As a manufacturer and user of APFO until its phase-out
beginning in 2000, the 3M Company (3M) has reported
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several periodic medical surveillance analyses of its fluo-
rochemical production workers at its Antwerp, Belgium;
Cottage Grove, MN; and Decatur, AL manufacturing
facilities (Ubel et al. 1980; Gilliland and Mandel 1996;
Olsen et al. 1998, 2000, 2003a). These analyses compared
workers’ clinical chemistry and hormone results in relation
to their serum measurements of either PFOA or perfluo-
rooctanesulfonate (PFOS, C8F17SO3
–).
In one of the aforementioned analyses, Olsen et al.
(2003a) reported a positive association between PFOA and
serum cholesterol and triglycerides among participants of a
fluorochemical medical surveillance program conducted in
2000 at the 3M Antwerp and Decatur facilities. They
considered this a spurious finding given the toxicological
evidence in mice and rats that shows PFOA, a peroxisome
proliferator alpha receptor agonist (PPARa), exerts effects
including increased beta-oxidation of fatty acids, inhibition
of the secretion of very low-density lipoproteins and cho-
lesterol from the liver, and a reduction of cholesterol and
triglycerides in serum and accumulation of lipids in the
liver (Maloney and Waxman 1999; Xie et al. 2003; Ken-
nedy et al. 2004). No associations were reported between
PFOA and either serum cholesterol or triglycerides for the
Cottage Grove male employees who participated in the
same fluorochemical medical surveillance program in 2000
(Olsen et al. 2003c).
In response to these occupational findings, Costa (2004)
reported preliminary cross-sectional analyses of data col-
lected from 2000 to 2004 of approximately 40 (per year)
Italian fluorochemical production workers. Costa observed
a modest increase of total cholesterol in workers exposed to
PFOA. There was no increase of other lipids, including
triglycerides, but the fraction of non-high density lipopro-
tein (non-HDL) cholesterol appeared elevated. Costa sug-
gested his findings might be consistent with the hypothesis
that PFOA could influence cholesteryl ester transfer protein
(CETP), a plasma glycoprotein that facilitates the transfer
of cholesteryl esters from apolipoprotein A-containing
lipoprotein (HDL) to apolipoprotein B-containing lipo-
proteins (Brousseau et al. 2004).
Kaplan (2004) summarized a cross-sectional analysis of
782 male and 243 female (combined eligible population
1,863) workers with potential exposure to PFOA at the Du-
Pont de Nemours Co. (DuPont) Parkersburg, West Virginia
facility. The highest measured PFOA concentration reported
was approximately 10 lg/ml with the average less than 1 lg/
ml. Statistically significant positive associations were iden-
tified for total cholesterol, low-density lipoproteins (LDL)
and triglycerides with serum PFOA concentrations although
the percent variation explained was also low. No association,
however, was seen with the HDL fraction thereby not sup-
porting a role between PFOA and CETP. Worker EKG
results and C-reactive protein measurements were also not
associated with PFOA. Although Kaplan offered no addi-
tional hypotheses or suggested causal models (Herna´n et al.
2002), PFOA has been shown to bind or be carried on blood
albumin (Han et al. 2003) and beta-lipoproteins (Kerstner-
Wood et al. 2003) in the rat, monkey and human; thus, a
positive non-causal correlation remains a possibility.
Re-examination of the Olsen et al. (2003a) analyses
suggested some limitations as they would relate to testing
the hypothesis that PFOA is positively associated with total
cholesterol and its non-HDL sub-fractions. First, the anal-
yses were not stratified by cholesterol lowering medication
status. A positive association could be masked by inclusion
of subjects whose serum cholesterol levels have been re-
duced by medication if such an increase was, in part,
associated with higher PFOA concentrations. Second, LDL
calculations were not restricted to those instances where
serum triglycerides were <400 mg/dl. The potential for bias
in the LDL calculation steadily increases with higher tri-
glyceride levels (Nakanishi et al. 2000). Third, the Antwerp
and Decatur facility study concentrated primarily on PFOS,
not PFOA. Both PFOS and PFOA have been shown to result
in hypolipidemia in rats at high concentrations and thus the
causal model hypothesized in these earlier analyses con-
centrated on testing for this effect, not hyperlipidemia. Fi-
nally, there was no overall analysis of the three
manufacturing facilities (Antwerp, Belgium; Cottage
Grove, MN; and Decatur, AL) as the Cottage Grove anal-
ysis has historically been reported separately (Ubel et al.
1980; Gilliland and Mandel 1996; Olsen et al. 2000, 2003a)
due to differences in fluorochemical production activities.
The purpose of this study was to analyze the 3M fluoro-
chemical medical surveillance program data collected in
2000 in order to examine the hypothesis that PFOA may be
positively associated with increased cholesterol, LDL, and
triglyceride levels across the three 3M fluorochemical pro-
duction facilities. Analyses focused on male employees who
self-reported that they were not taking cholesterol lowering
medications in order to minimize unexplained bias intro-
duced by including participants taking such medication.
Because PFOS concentrations were not previously associ-
ated with lowered serum cholesterol (Olsen et al. 2003a),
PFOS was not considered an important potential con-
founding variable in these PFOA analyses. Three covariates
were: age, BMI and alcohol. In addition to the lipids assayed,
hepatic enzyme and thyroid tests were also analyzed. Serum
triglyceride levels were also considered a potential con-
founder with hepatic enzyme analyses (Clark et al. 2003).
Materials and methods
The 2000 fluorochemical medical surveillance program at
3M was available on a voluntary basis to all Antwerp,
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Decatur, and Cottage Grove chemical plant employees and
those with site-wide responsibilities (e.g., environmental,
health and safety workers). Informed consent was obtained
to measure specific fluorochemical concentrations in the
blood of program participants, including PFOA. The
number of individuals eligible (i.e., potential to have had
occupationally related exposure) for the program included
approximately 340 Antwerp, 400 Decatur, and 200 Cottage
Grove employees.
Clinical chemistry variables considered in the analyses
were: alkaline phosphatase (IU/l), gamma glutamyl trans-
ferase (GGT, IU/l), aspartate aminotransferase (AST, IU/l),
alanine aminotransferase (ALT, IU/l), total and direct bili-
rubin (mg/dl), blood glucose (mg/dl), cholesterol (mg/dl),
LDL (mg/dl), HDL (mg/dl), and triglycerides (mg/dl).
These measurements were performed at Allina Laboratories
(St Paul, MN). LDL was an indirect calculation using the
Friedewald formula (Friedewald et al. 1972) [LDL = total
cholesterol – HDL – (triglycerides/5)] when serum trigly-
cerides did not exceed 400 mg/dl. Thyroid stimulating
hormone (TSH; lIU/ml); serum thyroxine (T4; lg/dl); free
thyroxine (free T4; ng/dl) and serum triiodothyronine (T3;
ng/dl) were also analyzed. These thyroid related hormones
were measured by LabCorp (Kansas City, MO). Thyroid
hormone analyses excluded five individuals who were al-
ready diagnosed with thyroid-related conditions and likely
taking medication. Results, however, did not differ if these
individuals were included in the analyses.
PFOA concentrations were also compared to frequency
of the metabolic syndrome in the study participants. Clin-
ical identification of the metabolic syndrome in men in-
cludes any three of the following: waist circumference
>40 in. (surrogate BMI ‡ 30); triglycerides ‡ 150 mg/dl;
HDL < 40 mg/dl; blood pressure ‡ 130/85 mmHg; and
fasting glucose ‡ 110 mg/dl (Expert Panel 2001). The
present study definition of the metabolic syndrome in-
cluded any three of the following four: BMI ‡ 30; trigly-
cerides ‡ 150 mg/dl; HDL < 40 mg/dl; and fasting
glucose ‡ 110 mg/dl.
At the time of the analyses that were done in 2000–2001
by Tandem Labs (formerly Northwest Bioanalytical, Salt
Lake City, UT), the analytical methods used were com-
parable to those reported by Hansen et al. (2001). The
analytical method consisted of a liquid:liquid extraction
procedure followed by evaporation and reconstitution of
the extract residue with 30:70 20 mM ammonium acetate
in water:20 mM ammonium acetate in methanol (v/v).
Eight or more calibration standards were prepared on the
day of each run by adding 100 ll of blank human serum
and 400 ll of 50 mM ammonium acetate in water to
polypropylene tubes. After a brief vortex mixing, 10.0 ll
of the appropriate spiking solution was added. In addition,
blank serum samples, both with and without internal
standard (tetra hydro-PFOS) were added. Samples were
analyzed by liquid chromatography/tandem mass spec-
trometry using a PE Sciex API 3000 (Applied Biosystems,
Foster City, CA). The instrument was operated in the
multiple reaction monitoring mode under optimized con-
ditions for detection of PFOA ions formed by turbionspray
ionization. All PFOA measurements were reported above
the lower limit of quantitation (5.8 ng/ml).
Statistical analyses included analysis of variance, anal-
ysis of covariance, logistic regression, and multiple
regression using JMP (Cary, NC) and Stata (College Sta-
tion, TX) software. Age, BMI and alcohol (drinks per day)
were considered covariates in the multivariable models.
For analysis of hepatic enzymes, serum triglycerides were
also considered a covariate. Distributions were examined to
assess normality using non-transformed variables and their
transformations (log, square root, inverse). In general, log
transformations improved normality assumptions of re-
sponse and explanatory variables and thus multiplicative
models (log transformations of explanatory and response
variables) were considered applicable. For the log trans-
formation of alcohol, 0.1 was added to drinks per day to
prevent the log of 0. Goodness of fit statistics, multicol-
linearity, and residual plots were examined to detect model
inadequacies. Crude and adjusted odds ratios for PFOA
categorized by deciles were determined via logistic
regression analyses for reference range values of the re-
sponse variable.
A comprehensive report is publicly available elsewhere
that details the present study methods and results (Olsen
and Zobel 2006).
Results
A total of 552 employees (Antwerp = 206; Cottage
Grove = 131; Decatur = 215) participated from these
facilities representing approximately 60% of Antwerp,
50% of Decatur and 65% of Cottage Grove eligible
employees. Demographic characteristics of those eligible
employees who did not participate are not known although
substantial differences between participants and non-par-
ticipants are unlikely given the routine practice of offering
voluntary medical surveillance programs at these facilities
for more than 20 years.
Of the 552 employee participants at these 3 facilities,
506 (92%) self-reported that they did not take cholesterol-
lowering medications: 196 (95%) for Antwerp, 122 (93%)
for Cottage Grove, and 188 (87%) for Decatur. Results will
focus on these 506 participants.
Presented in Table 1 are measures of central tendency
for the 506 participants for PFOA, PFOS, demographic
factors and the clinical chemistries. The number and per-
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cent of employees by specific reference points for demo-
graphic factors and clinical chemistry findings are pre-
sented in Table 2. Besides their younger age, there were
substantially fewer Antwerp employees (5%) who would
be categorized as obese (BMI ‡ 30) compared to Cottage
Grove (44%) or Decatur (32%) employees. More than 40%
of Antwerp and Cottage Grove employees reported drink-
ing one alcoholic beverage per day or more compared to
only 1% of Decatur employees. There were regional cul-
tural/lifestyle practices that likely account for this differ-
ence in alcohol consumption. Other statistically significant
differences between the three locations were observed for
blood glucose, HDL, triglycerides, alkaline phosphatase,
ALT, total bilirubin, and the ‘metabolic syndrome’. The
higher percentage of Antwerp male employees with total
bilirubin >1.5 mg/dl has been attributed to the likely
greater prevalence of Gilbert’s syndrome (Olsen et al.
1999). Only 1% of the Antwerp employees were catego-
rized as having the ‘metabolic syndrome’ compared to 20
and 13% among the Cottage Grove and Decatur employ-
ees, respectively.
Serum PFOA concentrations for the 506 employees
ranged from 0.007 to 92.03 lg/ml [arithmetic mean
2.21 lg/ml (95% confidence interval 1.66–2.77), median
1.10 lg/ml]. PFOA results are categorized by deciles in
Table 3. Mean PFOA decile concentrations ranged from
the lowest decile of 0.06 lg/ml (range 0.007–0.13 lg/ml)
to the highest decile of 12.15 lg/ml (range 3.71–92.03 lg/
ml) with corresponding median values of 0.06 and 4.94 lg/
ml, respectively.
The distributions of demographic factors by PFOA
decile are presented in Table 4. There were higher per-
centages of Antwerp employees in the first three deciles
and lower percentages in the highest two deciles (9 and
10). Likewise, there were lower percentages of Decatur
employees in the first three deciles and higher percentages
in the upper deciles (6–10), in particular decile 9. Because
of these disparities, mean BMI values were greater in the
Table 2 Number of employees
(%) by location for reference
points of demographic factors
and clinical chemistry results
Percentage values are given in
parentheses
a Chi square test of significance









Age < 40 years 127 (65) 57 (47) 76 (40) 0.0001
BMI ‡ 30 9 (5) 54 (44) 61 (32) 0.0001
Alcohol ‡ 1 drink/day 92 (47) 49 (40) 2 (1) 0.0001
Glucose ‡ 110 mg/dl 10 (5) 22 (18) 16 (9) 0.001
Cholesterol ‡ 200 mg/dl 119 (61) 69 (57) 114 (61) 0.72
Cholesterol ‡ 240 mg/dl 60 (31) 32 (26) 50 (27) 0.60
HDL < 40 mg/dl 16 (8) 36 (30) 72 (38) 0.0001
LDL ‡ 130 mg/dl 106 (55) 53 (48) 100 (55) 0.40
Triglycerides ‡ 150 mg/dl 46 (23) 58 (48) 103 (55) 0.0001
Alkaline phosphatase ‡ 120 IU/l 0 (0) 0 (0) 5 (3) 0.01
AST ‡ 40 IU/l 4 (2) 8 (7) 11 (6) 0.09
ALT ‡ 40 IU/l 14 (7) 34 (28) 51 (27) 0.0001
GGT ‡ 40 IU/l 25 (13) 27 (22) 34 (18) 0.09
Total bilirubin > 1.5 mg/dl 13 (7) 1 (1) 0 (0) 0.0001
Direct bilirubin > 0.4 mg/dl 0 (0) 0 (0) 2 (1) 0.18
TSH
<0.35 lIU/ml 1 (1) 1 (1) 1 (1) 0.92
>5.5 lIU/ml 5 (3) 5 (4) 8 (4) 0.60
T4
<4.5 lg/dl 1 (1) 0 (0) 0 (0) 0.46
>12.0 lg/dl 0 (0) 0 (0) 0 (0) 1.0
Free T4
<0.70 ng/dl 1 (1) 0 (0) 2 (1) 0.49
>1.53 ng/dl 3 (2) 1 (1) 1 (1) 0.60
T3
<60 ng/dl 0 (0) 0 (0) 0 (0) 1.0
>181 ng/dl 2 (1) 3 (3) 2 (1) 0.46
Metabolic syndromeb 2 (1) 24 (20) 25 (13) 0.0001
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upper deciles and alcohol consumption was lower,
reflecting the demographic differences seen across the
three facilities in Tables 1 and 2.
Presented in Figs. 1 and 2 are scatterplots of the natural
logs of the blood lipids and PFOA. Pearson correlation
coefficients and P values (in parentheses) between PFOA
and the lipid parameters were: cholesterol (r = 0.05,
P = 0.32), LDL (r = 0.006, P = 0.90), HDL (r = –0.17,
P < 0.0001), and triglycerides (r = 0.21, P < 0.0001).
Unadjusted and adjusted coefficients for PFOA when re-
gressed with total cholesterol, LDL, HDL, and triglycerides
are presented in Table 5. Analyses are also presented for
each location in Table 5. PFOA was not a statistically
significant coefficient in the regression models for total
cholesterol or LDL. In the regression model for HDL that
contained all three locations, the adjusted PFOA coefficient
was statistically significant (P = 0.01) but only explained
1% of the variance in the model. Separate models analyzed
for each of the three locations showed no statistically sig-
nificant findings between PFOA and HDL. The model for
triglycerides for the combined three locations indicated a
statistically significant positive coefficient (P < 0.0001) for
PFOA which explained approximately 4% of the variance
of the response variable. Stratified by location showed
Antwerp with a statistically significant positive PFOA
coefficient (P < 0.0004) and Decatur had a marginally
positive coefficient for PFOA (P = 0.07). No statistically
significant coefficient for PFOA (P = 0.38) was found with
triglycerides for the Cottage Grove location.
Presented in Table 6 are the mean and 95% confidence
intervals (CI) values for cholesterol, LDL, HDL, and tri-
glycerides by PFOA deciles, adjusted for age, BMI, and
alcohol. Mean serum triglyceride levels were highest in the
upper three PFOA deciles.
Table 7 presents adjusted odds ratios and 95% confi-
dence intervals by reference range cutoff points listed in
Table 2, using the lowest PFOA decile as the reference.
Serum PFOA concentrations were not associated, posi-
tively or negatively, with cholesterol or LDL. For
HDL < 40 mg/dl, the non-adjusted odds ratio for the
highest decile was 3.0 (95% CI 1.2–7.5). Adjusted for age,
BMI and alcohol, the highest decile odds ratio became 2.6
(95% CI 1.0–6.8) (Table 5). Adjusted also for location, this
odds ratio became 1.8 (95% CI 0.7–4.8). Adjusted odds
ratios for triglyceride levels ‡150 mg/dl were also highest
Table 4 Distribution of demographic factors by PFOA decile
PFOA Antwerp Cottage Grove Decatur Age BMI BMI ‡ 30 Drinks/day ‡1 drink/day
Decile N (%) N (%) N (%) Mean (SD) Mean (SD) N (%) Mean (SD) N (%)
1 28 (55) 17 (33) 6 (12) 39 (11) 27.1 (4.8) 13 (25) 0.7 (0.7)i 21 (41)
2 25 (49) 13 (26) 13 (25) 41 (9) 26.7 (4.1)i 7 (14) 0.7 (0.9)i 17 (33)
3 28 (55) 11 (22) 12 (23) 38 (8) 26.4 (3.9)i, j 8 (16) 0.7 (1.0)i 15 (29)
4 20 (40) 13 (26) 17 (34) 38 (10) 27.8 (4.3) 13 (26) 0.7 (1.0)i 13 (26)
5 22 (43) 11 (22) 18 (35) 40 (10) 27.2 (5.0) 8 (17) 0.7 (1.0)i 16 (32)
6 21 (43) 7 (14) 21 (43) 40 (9) 27.4 (4.8) 12 (24) 0.7 (1.0)i 14 (29)
7 20 (40) 9 (18) 21 (42) 39 (9) 26.9 (3.9)i 10 (20) 0.7 (0.9)i 14 (28)
8 18 (33) 11 (20) 25 (46) 41 (10) 27.5 (5.4) 17 (31) 0.6 (0.9)i 16 (30)
9 9 (18) 7 (14) 33 (67) 39 (9) 28.9 (4.9)b, c, g 21 (43) 0.3 (0.5)a–h 5 (10)
10 5 (10) 23 (46) 22 (44) 39 (9) 28.3 (4.0)c 15 (30) 0.5 (0.7) 12 (24)
P < 0.0001k P < 0.03l P < 0.14m
a–j Statistically significantly (P < 0.05) different than PFOA decile 1, 2, 3,…, 10, respectively
k, l, m P value associated with Chi square test for location, BMI distribution and ‡1 drink/day, respectively
Table 3 Number of employees, arithmetic mean, 95% confidence
interval (95% CI), median and range, by PFOA decile
PFOA PFOA
Decile N Mean 95% CI Median Range
1 51 0.06h–j 0.05–0.07 0.06 0.007–0.13
2 51 0.20i, j 0.19–0.21 0.19 0.13–0.29
3 51 0.36i, j 0.35–0.37 0.36 0.30–0.44
4 50 0.55i, j 0.53–0.57 0.54 0.44–0.71
5 51 0.91j 0.87–0.94 0.91 0.72–1.10
6 49 1.26j 1.23–1.28 1.25 1.11–1.40
7 50 1.64j 1.60–1.67 1.63 1.42–1.85
8 54 2.17a, j 2.12–2.23 2.18 1.86–2.50
9 49 3.00a–d, j 2.90–3.10 2.96 2.51–3.69
10 50 12.15a–i 7.21–17.10 4.94 3.71–92.03
a–j Statistically significantly (P < 0.05) different than PFOA decile(s)
1, 2, 3,…, 10, respectively
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for PFOA deciles 8–10 as seen with adjusted mean tri-
glyceride values reported in Table 7.
Presented in Figs. 3 and 4 are scatterplots of natural logs
of hepatic clinical chemistries by PFOA. Pearson correla-
tion coefficients and P values (in parentheses) between
PFOA and the hepatic parameters were: alkaline phos-
phatase (r = 0.08, P = 0.06), AST (r = –0.01 P = 0.83),
ALT (r = 0.005, P < 0.005), and GGT (r = 0.02,
P < 0.02). Analyses presented in Table 8 of the regression
models showed marginal statistically significant coeffi-
cients for PFOA when adjusted for age, BMI, and alcohol
for ALT (P = 0.06) and GGT (P = 0.05) but not when
adjusted for age, triglycerides, and alcohol for ALT
(P = 0.40) and GGT (P = 0.55). Total bilirubin was sta-
tistically significantly negatively associated with PFOA
regardless of covariates used. Stratified by location,
Decatur had marginally statistically significant positive
coefficients, regardless of covariates adjusted, ranging be-
tween 0.01 < P < 0.07 for alkaline phosphatase, ALT,
GGT, and total bilirubin. The amount of variance of the
hepatic response variables explained by PFOA in these
models was minimal ranging from <1 to 3%. No statisti-
cally significant PFOA coefficients for the hepatic enzymes
were observed in either the Antwerp or Cottage Grove
regression models.
No discernable trends in adjusted mean hepatic enzyme
values were apparent when analyzed by deciles (Table 9).
There were no statistically significant odds ratios (non-
adjusted or adjusted) for the reference points AL-
T ‡ 40 IU/l or GGT ‡ 40 IU/l when compared to decile 1
(Table 10). Odds ratios for alkaline phosphatase, AST, and
total bilirubin are not shown because of the failure of the
logistic models to converge because of the very few data
points that were out-of-reference range (Table 2) for these
clinical parameters.
Presented in Figs. 5 and 6 are scatterplots of natural logs
of thyroid hormones by PFOA. Pearson correlation coef-
ficients and P values (in parentheses) between PFOA and
the thyroid hormones were: TSH (r = 0.08, P = 0.07), T4
(r = –0.04, P = 0.32), free T4 (r = –0.14, P < 0.002), and
T3 (r = 0.07, P = 0.11). For all locations combined, there
were no statistically significant adjusted coefficients for
PFOA in the models except for Free T4 (negative coeffi-
cient for PFOA) and T3 (positive coefficient for PFOA)
(Table 11). However, the full models only explained 5 and
2% of the variance of free T4 and T3, respectively. The
thyroid results were considered not clinically relevant as
results from these models were well within normal refer-
ence ranges for the four thyroid parameters when serum
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Fig. 2 Scatterplots of the natural log PFOA (ng/ml) by the natural
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Fig. 1 Scatterplots of the natural log PFOA (ng/ml) by the natural
log total cholesterol and LDL
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between 0.005 and 100 lg/ml (Table 12). Presented in
Table 13 are the mean thyroid hormone-related values
adjusted for age, BMI and alcohol. The mean TSH value in
the fourth decile of Table 13 is influenced by one subject
whose TSH value was 65.3 lIU/ml (see overall results in
Table 1) who was not diagnosed at the time as hypothy-
roid. If removed, the mean of the fourth decile became
2.15 lIU/ml and the decile statistically significant differ-
ences with this fourth decile in Table 13 disappear. The
adjusted mean for the highest decile for free T4 was sta-
tistically significantly lower than that of the first decile.
There were no statistically significant differences between
decile-adjusted means for T3 in Table 13. Because so few
thyroid values were out-of-reference range (Table 2), the
findings from the logistic analyses are not presented be-
cause of the models’ lack of convergence.
PFOA was not associated with the metabolic syndrome.
Age-adjusted odds ratios (95% CI in parentheses) for the
Table 5 Non-adjusted and
adjusted natural log (ln) PFOA
coefficients with ln lipid
measurements
a See study methods. Adjusted





Coefficient SE P value Coefficient SE P value
Ln cholesterol
All locations 0.0059 0.0060 0.32 0.0076 0.0059 0.20
Antwerp 0.0051 0.0106 0.63 0.0130 0.0096 0.18
Cottage Grove 0.0034 0.0089 0.70 0.0021 0.0100 0.83
Decatur 0.0221 0.0139 0.11 0.0266 0.0141 0.06
Ln LDL
All locations 0.0012 0.0089 0.89 0.0021 0.0090 0.81
Antwerp –0.0037 0.0157 0.81 0.0106 0.0147 0.47
Cottage Grove –0.0022 0.0139 0.87 0.0049 0.0145 0.73
Decatur 0.0258 0.0199 0.20 0.0302 0.0200 0.13
Ln HDL
All locations –0.0307 0.0079 0.0001 –0.0183 0.0069 0.01
Antwerp –0.0057 0.0136 0.68 –0.0095 0.0131 0.47
Cottage Grove –0.0153 0.0122 0.21 –0.0192 0.0120 0.11
Decatur –0.0256 0.0149 0.09 –0.0207 0.0141 0.14
Ln triglycerides
All locations 0.0892 0.0185 0.0001 0.0711 0.0169 0.0001
Antwerp 0.0840 0.0288 0.004 0.0980 0.0270 0.0004
Cottage Grove 0.0343 0.0316 0.28 0.0280 0.0314 0.38
Decatur 0.0715 0.0400 0.08 0.0689 0.0376 0.07
Table 6 Adjusted mean and 95% confidence intervals (95% CI) for lipid clinical chemistry results, by PFOA decile
PFOA Cholesterol LDL HDL Triglycerides
Decile Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
1 214 203–225 137 127–147 50j 46–53 145j 116–173
2 211 199–222 135 125–145 51j 48–54 124h–j 95–153
3 209 198–220 128 118–138 51j 48–54 153j 124–182
4 210 199–222 133 123–143 50j 46–53 145j 116–175
5 217 206–228 140 130–150 48 45–51 162j 133–191
6 218 206–229 141 130–151 48 45–51 160j 131–190
7 214 203–225 133 123–143 50j 47–53 158j 128–187
8 215 204–226 136 126–146 47 44–50 172 144–201
9 221 210–233 140 130–150 48 44–52 165j 135–194
10 216 204–227 133 123–144 44a–d 41–47 208a–g, i 179–238
Adjusted for age, BMI and alcohol
a–j Statistically significantly (P < 0.05) different than PFOA decile(s) 1, 2, 3,…, 10, respectively
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6th, 7th, 8th, 9th and 10th PFOA deciles were 1.0 (0.3–
3.5), 0.5 (0.1–2.0), 0.9 (0.3–3.0), 1.1 (0.3–3.6) and 1.0
(0.3–3.6), respectively.
Other analyses included those subjects (n = 46) who
self-reported cholesterol lowering medication usage. These
46 subjects, compared to the 506 non-prescribed subjects,
had comparable mean PFOA concentrations (1.98 lg/ml
vs. 2.21 lg/ml) but were statistically significantly older (49
vs. 40) and had higher mean BMI (28.8 vs. 27.4), serum
glucose (103 vs. 91), triglycerides (226 vs. 159), and sev-
eral liver enzyme results (alkaline phosphatase 73 vs. 66,
ALT 36 vs. 30, GGT 36 vs. 28). Cholesterol (221 vs. 214),
LDL (134 vs. 136), and HDL (47 vs. 49) were not statis-
tically significantly different between the two groups. No
Table 7 Adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for lipid clinical chemistry reference points, by PFOA decile
PFOA Chol ‡ 200 mg/dl LDL ‡ 130 mg/dl HDL £ 40 mg/dl Triglycerides ‡ 150 mg/dl
Decile ORa 95% CI ORb 95% CI ORa 95% CI ORb 95% CI ORa 95% CI ORb 95% CI ORa 95% CI ORb 95% CI
1 1.0 – 1.0 – 1.0 – 1.0 – 1.0 – 1.0 – 1.0 – 1.0 –
2 0.4 0.2–1.0 0.4 0.2–1.0 0.7 0.3–1.6 0.7 0.3–1.7 1.1 0.4–3.2 1.0 0.4–3.0 0.7 0.3–1.8 0.6 0.2–1.6
3 0.9 0.4–2.0 0.9 0.4–2.0 0.7 0.3–1.6 0.7 0.3–1.6 0.5 0.1–1.5 0.4 0.1–1.3 1.0 0.4–2.4 0.9 0.4–2.2
4 0.9 0.4–2.1 0.9 0.4–2.0 0.8 0.4–1.8 0.8 0.4–1.9 2.0 0.8–5.4 1.7 0.6–4.7 1.3 0.5–3.1 1.1 0.4–2.6
5 1.7 0.7–4.0 1.6 0.7–3.9 1.4 0.6–3.1 0.4 0.6–3.2 1.0 0.4–2.9 0.8 0.3–2.4 1.2 0.5–3.0 1.0 0.4–2.5
6 1.0 0.4–2.2 0.9 0.4–2.1 0.9 0.4–2.0 0.9 0.4–2.1 1.7 0.7–4.7 1.4 0.5–3.9 1.7 0.7–4.0 1.3 0.5–3.2
7 0.8 0.4–1.9 0.8 0.3–1.8 0.7 0.3–1.5 0.7 0.4–1.6 0.6 0.2–1.8 0.5 0.1–1.4 0.9 0.4–2.2 0.7 0.3–1.8
8 1.0 0.4–2.2 0.9 0.4–2.1 1.1 0.5–2.4 1.1 0.5–2.5 1.4 0.5–3.7 1.0 0.4–2.8 2.7 1.2–6.5 2.1 0.9–5.2
9 1.4 0.6–3.3 1.3 0.6–3.1 1.2 0.5–2.7 1.2 0.5–2.8 0.9 0.3–2.4 0.6 0.2–1.7 2.4 1.0–5.9 1.7 0.7–4.3
10 1.1 0.5–2.6 1.1 0.5–2.6 1.2 0.5–2.8 1.4 0.6–3.3 2.6 1.0–6.8 1.8 0.7–4.8 2.4 1.0–5.8 1.8 0.8–4.4
a Adjusted for age, BMI and alcohol
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Fig. 3 Scatterplots of the natural log PFOA (ng/ml) by the natural


















Fig. 4 Scatterplots of the natural log PFOA (ng/ml) by the natural
log ALT and GGT
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Table 8 Non-adjusted and
adjusted natural log (ln) PFOA
coefficients with ln hepatic
clinical chemistry
measurements
a Study methods. Adjusted for
Ln age, Ln BMI, Ln alcohol
b Study methods. Adjusted for






Coefficient SE P value Coefficient SE P value
Ln alkaline phosphatase
All locations 0.0155 0.0082 0.06 0.0093a 0.0081 0.25
0.0037b 0.0081 0.65
Antwerp –0.0025 0.0137 0.85 –0.0060 0.0139 0.67
–0.0170 0.0140 0.22
Cottage Grove –0.0141 0.0113 0.21 –0.0127 0.0117 0.28
–0.0140 0.0117 0.24
Decatur 0.0394 0.0191 0.04 0.0460 0.0192 0.02
0.0394 0.0192 0.04
Ln AST
All locations –0.0018 0.0086 0.83 –0.0051 0.0086 0.55
–0.0089 0.0087 0.31
Antwerp –0.0048 0.0137 0.73 –0.0029 0.0138 0.83
–0.0066 0.0142 0.64
Cottage Grove –0.0281 0.0141 0.05 –0.0258 0.0146 0.08
–0.0271 0.0145 0.07
Decatur 0.0205 0.0200 0.31 0.0114 0.0203 0.57
0.0062 0.0203 0.76
Ln ALT
All locations 0.0402 0.0143 0.005 0.0249 0.0132 0.06
0.0115 0.0136 0.40
Antwerp –0.0122 0.0220 0.58 –0.0085 0.0222 0.70
–0.0293 0.0222 0.19
Cottage Grove –0.0131 0.0215 0.54 –0.0096 0.0209 0.65
–0.0008 0.0208 0.69
Decatur 0.0954 0.0300 0.002 0.0704 0.0287 0.02
0.0581 0.0287 0.04
Ln GGT
All locations 0.0409 0.0174 0.02 0.0326 0.0166 0.05
0.0097 0.0163 0.55
Antwerp 0.0170 0.0307 0.58 0.0269 0.0294 0.36
–0.0047 0.0295 0.87
Cottage Grove –0.0088 0.0292 0.76 –0.0198 0.0286 0.49
–0.0233 0.0270 0.39
Decatur 0.0754 0.0344 0.03 0.0800 0.0344 0.02
0.0599 0.0329 0.07
Ln total bilirubin
All locations –0.0406 0.0101 0.0001 –0.0325 0.0099 0.001
–0.0267 0.0101 0.01
Antwerp –0.0117 0.0178 0.51 –0.0122 0.0182 0.50
–0.0093 0.0188 0.62
Cottage Grove –0.0060 0.0138 0.66 –0.0098 0.0142 0.49
–0.0067 0.0141 0.64
Decatur –0.0528 0.0203 0.01 –0.0537 0.0209 0.01
–0.0462 0.0206 0.03
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significant differences were observed with thyroid hor-
mones. Twenty percent of these 46 subjects were catego-
rized as having the metabolic syndrome compared to 7% of
those not prescribed cholesterol-lowering medication. Not
unexpectedly based on the results already presented, a
greater percentage of those prescribed cholesterol-lowering
medications were Cottage Grove and Decatur employees
(79%) than those not prescribed medications (61%).
Analyses with the clinical chemistries were similar whether
they excluded or included these 46 employees who self-
reported cholesterol lowering medications (data not
shown).
Discussion
Based on an analysis of 506 male participants of the 2000
fluorochemical medical surveillance program offered at the
3M Antwerp, Cottage Grove, and Decatur fluorochemical
production facilities who self-reported that they did not
take cholesterol lowering medications, there was no evi-
dence that these employees’ serum PFOA concentrations
were positively, or negatively, associated with serum total
cholesterol or LDL. These data analyses support the
argument that the PFOA and cholesterol association ob-
served in an analysis by Olsen et al. (2003a) of Antwerp
and Decatur workers in this database could have been a
spurious finding or may have been the result of residual
confounding between the different demographic popula-
tions as seen in Tables 1 and 2. Addition of the Cottage
Grove workforce, that was actively engaged in the manu-
facture of the ammonium salt of perfluorooctanoic acid and
had the highest serum PFOA concentrations of the three
facilities, only further demonstrated the lack of an associ-
ation between PFOA and cholesterol in this workforce.
Unlike rats and mice, there was no reduction in serum
cholesterol in cynomolgus monkeys dosed with PFOA
(ammonium salt) for 6 months (Butenhoff et al. 2002).
A weakly negative association was observed with HDL
that was possibly due to uncontrolled (i.e., residual) con-
founding, based on lower HDL values observed among the
Cottage Grove and Decatur workers than the Antwerp
workers and their markedly different demographic factors
(e.g., BMI). When the analyses were stratified by location,
no statistically significant associations were observed be-
tween HDL and PFOA. In another occupational study,
Kaplan (2004) did not report an association between HDL
and serum PFOA concentrations. Neither did Emmett et al.
(2006a) in a community-based exposure study whose
median PFOA concentrations (approximately 0.354 lg/ml)
were 60 times higher than that of general population
studies (Calafat et al. 2006; Olsen et al. 2003b). To further
clarify any possible association with HDL, the A apolipo-
proteins, which form the major proteins found in HDL,
could be measured although this was not part of the present
study. Apolipoprotein A1 was not associated with serum
PFOA of comparable concentrations in a small analysis of
Italian production workers (Costa 2004).
Serum triglyceride levels were positively associated
with PFOA. Although a biological association cannot be
ruled out, it is also possible that this association might have
been due, at least partially, to residual confounding as a
consequence of the disproportionate number of Cottage
Grove and Decatur employees with higher PFOA concen-
trations than the Antwerp employees. The same positive
association was also observed between PFOS and serum
Table 9 Adjusted mean and 95% confidence intervals (95% CI) for hepatic clinical chemistry results, by PFOA decile
Total Direct
PFOA Alk Phos AST ALT GGT Bilirubin Bilirubin
Decile Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
1 66 61–71 26e,f 24–28 29 25–33 32f 27–38 0.9i 0.86–1.02 0.1 0.09–0.12
2 59g,i,j 54–64 25 23–27 29 25–33 25 19–31 0.9i 0.84–1.00 0.1 0.09–0.12
3 64g 59–69 26e,f 24–28 30 26–34 27 21–33 1.0f–j 0.89–1.06 0.1 0.09–0.12
4 65 61–70 24 22–26 28i,j 24–32 28 22–34 0.9i 0.82–0.99 0.1 0.08–0.11
5 64g 60–69 22a,c,g–i 20–25 27i,j 23–31 24i 18–30 0.9 0.79–0.95 0.1i 0.10–0.13
6 66 61–71 22a,c,g–i 20–24 25g,i,j 21–28 21a,i 15–27 0.9c 0.78–0.95 0.1 0.08–0.11
7 72b,c,e,h 67–77 26e,f 24–28 31f 27–35 28 22–34 0.9c 0.77–0.94 0.1 0.08–0.11
8 65g 60–70 26e,f 24–28 29 26–33 29 23–35 0.9c 0.77–0.93 0.1i 0.10–0.13
9 70b 66–75 26e,f 24–28 34d–f 30–38 33e,f 27–39 0.8a–d 0.69–0.85 0.1e,h 0.07–0.10
10 68b 63–72 24 22–26 34d–f 30–38 30 24–36 0.8c 0.75–0.92 0.1 0.08–0.12
Adjusted for age, BMI, and alcohol
a–j Statistically significantly (P < 0.05) different than PFOA decile(s) 1, 2, 3,…, 10, respectively
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triglycerides (Olsen et al. 2003c). This prior association
with PFOS is inconsistent with the well-established hyp-
olipidemia reported in PFOS-related toxicological studies
with concentrations much higher than in the present study
(Seacat et al. 2002, 2003). On the other hand, PFOA was
statistically significantly positively associated with trigly-
cerides in the high-dose (30/20 mg/kg) monkey group
whose steady state serum PFOA concentration was
158 ± 10 lg/ml (range 20–467 lg/ml) (Butenhoff et al.
2002). This association was observed in measurements
taken after 1 month of dosing at which time the group
mean triglyceride level was significantly higher than con-
trol values as well as within group pretreatment values. At
the end of the study the mean triglyceride was elevated
compared to time related controls but not to the animals’
pre-treatment values. However, only two primates were
evaluated in the high-dose group at end of study. Inspection
of individual values for PFOA serum concentration and
serum triglyceride values did not reveal any meaningful
associations between these two parameters.
Of the four lipid measurements assessed in this study,
serum triglycerides have three times more intra-individual
biological variation than either total cholesterol, LDL, or
HDL (Stein and Myers 1994). Serum triglycerides are
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-6.0 -4.0 -2.0 0.0 2.0 4.0 6.0
Fig. 5 Scatterplots of the natural log PFOA (ng/ml) by the natural
log TSH and T3
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fasting requirements for blood collection, including caffe-
inated drinks. It can also be hypothesized that the associ-
ations observed for serum triglycerides and PFOA might be
the consequence of the non-adherence to fasting require-
ments by some shift production workers and/or the effect
of postprandial metabolic responses in shift workers. Sev-
eral studies have indicated postprandial serum triglyceride
levels are higher among night shift workers than day
workers (Al-Naimi et al. 2004; Morgan et al. 1998; Kar-
lsson et al. 2001; Lund et al. 2001). If a subset of subjects
(i.e., production workers with higher PFOA serum con-
centrations) who worked night shift were less likely to
adhere to the fasting requirements and/or have postprandial
metabolic profiles similar to other night shift workers, then
a non-causal positive association between PFOA concen-
trations and serum triglycerides could be observed when all
subjects are included in the analysis. Unfortunately, at the
time of data blood collection shift status information was
not obtained; consequently with this database it is not
possible to further address this methodological question.
Countering this possible hypothesis is the fact that blood
glucose, also requiring a fasting sample, was not associated
with PFOA at any site. However, hyperglycemia has not
been consistently associated with night shift workers
(Al-Naimi et al. 2004; Karlsson et al. 2003). Also, the
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Fig. 6 Scatterplots of the natural log PFOA (ng/ml) by the natural
log T4 and free T4
Table 11 Non-adjusted and
adjusted natural log (ln) PFOA
coefficients with ln thyroid-
related hormone measurements
a See study methods. Adjusted





Coefficient SE P value Coefficient SE P value
Ln TSH
All locations 0.0395 0.0204 0.05 0.0360 0.0207 0.08
Antwerp 0.0509 0.0329 0.12 0.0391 0.0333 0.24
Cottage Grove –0.0016 0.0310 0.96 –0.0111 0.0322 0.73
Decatur 0.0343 0.0497 0.49 0.0365 0.0513 0.48
Ln T4
All locations –0.0037 0.0054 0.50 –0.0057 0.0054 0.29
Antwerp –0.0022 0.0099 0.83 –0.0041 0.0099 0.68
Cottage Grove –0.0124 0.0072 0.09 –0.0093 0.0072 0.20
Decatur –0.0012 0.0126 0.92 –0.0083 0.0127 0.51
Ln free T4
All locations –0.0138 0.0044 0.002 –0.0117 0.0043 0.01
Antwerp –0.0108 0.0078 0.17 –0.0140 0.0078 0.07
Cottage Grove –0.0093 0.0058 0.11 –0.0071 0.0059 0.23
Decatur –0.0138 0.0103 0.18 –0.0184 0.0105 0.08
Ln T3
All locations 0.0107 0.0052 0.04 0.0105 0.0053 0.05
Antwerp 0.0222 0.0077 0.005 0.0216 0.0077 0.006
Cottage Grove 0.0026 0.0096 0.79 0.0006 0.0099 0.95
Decatur 0.0317 0.0117 0.008 0.0271 0.0119 0.02
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observed at the Cottage Grove site which had both pro-
duction and non-production workers. Nevertheless, a po-
sitive association between serum triglycerides and PFOA
was reported by Kaplan (2004) whose study population
also consisted of production (shift workers) and non-pro-
duction (non-shift workers) participants. To further clarify
a possible positive association, between workers’ PFOA
concentrations and serum triglyceride levels, adjustment
for shift work becomes a methodological necessity for
subsequent occupational research analyses.
Although hepatic enzymes, in particular GGT, AST and
ALT are known to be elevated with heavy alcohol con-
sumption, these liver enzymes can also be elevated due to
obesity and dyslipidemia (Collantes et al. 2004; Mofrad
and Sanyal 2003; Ruhl and Everhart 2003) as non-alco-
holic fatty liver disease has substantially increased in
prevalence in the US population, as indicated by the third
National Health and Nutrition Examination Survey
(NHANES) (Clark et al. 2003). Measured hepatic clinical
chemistry enzymes in the present study were not consis-
tently associated with employees’ serum PFOA concen-
trations adjusted for age, alcohol, and either BMI or serum
triglycerides. A weakly positive association between
alkaline phosphatase, ALT and GGT with PFOA was ob-
served among the Decatur male participants. Several epi-
demiologic research studies of the Decatur workforce have
not reported associations with liver disease (malignant or
non-malignant conditions) using a variety of data sources
including death certificates (Alexander et al. 2003), epi-
sodes of care (Olsen et al. 2004) and self-reports (Alex-
ander and Grice 2006). Neither a worker population study
(Kaplan 2004) nor a community-based PFOA-exposed
population (Emmett et al. 2006a, b) has reported associa-
tions between PFOA and hepatic clinical chemistries. In
the Emmett et al. (2006a) study, there was no relationship
between the blood levels of PFOA and the results for
cholesterol, hepatic-related tests (serum protein, albumin,
bilirubin, serum alkaline phosphatase, AST, ALT and
GGT), or being treated for or informed by a physician that
a community participant had liver disease (cirrhosis, hep-
atitis, and any other liver condition).
In the present study, there were no consistent associa-
tions between TSH, T4, free T4 or T3 with PFOA across
the individual facility locations. Overall, T4 was negatively
associated with PFOA and T3 was positively associated but
these trends were well within normal reference ranges. The
lack of thyroid related hormone associations is also con-
sistent with results from Kaplan (2004) and Emmett et al.
(2006a). In a 6-month oral capsule PFOA dose study of
cynomolgus monkeys, Butenhoff et al. (2002) reported no
Table 12 Predicted thyroid-related measurements (reference range
in parentheses) based on regression models for 40 year-old male with
















0.005 1.58 8.22 1.15 119
0.01 1.62 8.19 1.15 119
0.10 1.76 8.08 1.11 121
0.50 1.87 8.01 1.09 124
1.00 1.91 7.98 1.09 125
5.00 2.03 7.90 1.06 128
10.00 2.07 7.87 1.06 128
50.00 2.20 7.80 1.04 131
100.00 2.26 7.77 1.03 132
Table 13 Adjusted mean and 95% confidence intervals for thyroid measurements, by PFOA decile
PFOA TSH T4 Free T4 T3
Decile Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
1 2.07d 1.13–3.01 8.29 7.92–8.66 1.15e,g,j 1.11–1.19 124 118–131
2 2.00d 1.04–2.96 8.45 8.07–8.83 1.11 1.07–1.15 125 118–131
3 1.89d 0.94–2.84 8.08 7.70–8.46 1.14e,j 1.10–1.18 124 118–131
4 3.43a–c,f 2.48–4.38 8.04 7.67–8.41 1.12 1.08–1.16 126 120–133
5 2.61 1.65–3.55 7.98f 7.60–8.35 1.07a,c 1.03–1.11 126 120–133
6 2.07d 1.11–3.03 8.53e,j 8.15–8.91 1.10 1.05–1.14 128 121–134
7 2.21 1.26–3.16 8.07 7.70–8.44 1.09a 1.06–1.14 129 123–135
8 2.36 1.46–3.32 8.40 8.03–8.76 1.08 1.06–1.14 130 124–136
9 2.84 1.87–3.81 8.42 8.03–8.80 1.11 1.06–1.15 129 123–136
10 2.40 1.46–3.37 7.94f 7.56–8.32 1.07a,c 1.03–1.11 128 123–136
Adjusted for age, BMI and alcohol
a–j Statistically significantly (P < 0.05) different than PFOA decile(s) 1, 2, 3,…, 10, respectively
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clear changes in thyroid hormone homeostasis for TSH, T4
or free T4. Three high-dose monkeys (serum concentra-
tions mentioned above) that were removed from dosing due
to toxicity had T3 values that trended downward compared
to pretreatment measures. This is opposite the observation
in the present study. Finally, a negative bias in thyroid-
related analog methods, using another perfluoroalkyl acid
(PFOS), has recently been reported by Chang et al. (2007).
Conclusion
PFOA concentrations measured in this workforce of 506
male fluorochemical production workers were not associ-
ated with total cholesterol, LDL, hepatic enzymes or thy-
roid hormones. Residual confounding likely explained an
association between PFOA and HDL. Several hypotheses
are offered for the inconsistent associations observed be-
tween PFOA and triglycerides. Although a biological
explanation cannot be ruled out, other hypotheses are also
plausible. These include non-adherence to fasting require-
ments for morning blood collection by night shift produc-
tion workers and/or increased triglyceride levels that have
been found in night shift workers, in general. Because
PFOA has been shown to bind or be carried to blood
albumin and beta-lipoproteins in the rat, monkey and hu-
man, a non-causal positive correlation also remains another
possible explanation.
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